Eran Ophir, PhD, Compugen Ltd.,Tel Aviv, Israel, discusses COM503, discusses the preclinical studies on COM503, a potential first-in-class, high affinity anti- IL18 binding protein antibody, which shows potent antitumor activity in various models and is a promising approach to harness cytokines to treat cancer.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.